臨床研究のトピックス

Topics for clinical research.

　骨粗鬆症治療薬に関しては，新規骨粗鬆症治療薬の第Ⅲ相試験の結果や既存治療薬のより長期の効果が発表された。一方，オダナカチブ（Odanacatib）についてもいくつかの演題が発表されたものの，学会直前に本薬の臨床開発の中止が発表された。また骨粗鬆症治療薬の稀な有害事象のため，骨粗鬆症患者の治療率が低いことが，骨粗鬆症治療の危機であると強調された。さらに代謝性骨疾患に対する新たな治療薬の効果が発表されるなど，臨床的に重要な話題の多い学会であった。

　Results from phase 3 study of a new drug along with effects of longer duration of a currently used drug for osteoporosis were presented. While there were several papers concerning odanacatib, the clinical development of this drug was announced to be terminated just before the meeting. In addition, low treatment rate for patients with osteoporosis because of fear for rare adverse events was emphasized to be a crisis in the treatment of osteoporosis. Finally, a new treatment for hypophosphatemic diseases was introduced. There are many clinically important topics in this meeting.